Compumedics (ASX:CMP) secured multiple Somfit sales to US-based pharmaceutical contract research organization and Finland-based Orion Pharma, with nearly $2 million of combined revenues from initial transactions, according to a Monday filing with the Australian bourse.
Somfit is a wearable home sleep test device designed to help diagnose sleep-related breathing disorders.
The first transaction involved a clinical drug trial facilitated by the contract research organization in the US, and the second involved the deployment of Somfit in a multi-country, multi-center clinical study across Europe, the filing said.
Shares fell more than 1% in midday trade Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.